Alturas Minerals Corp
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1997-01-01
- Employees
- 2
- Market Cap
- $476.1M
- Website
- http://www.altimmune.com
- Introduction
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Altimmune Secures $100 Million Credit Facility to Advance Pemvidutide Development for MASH and Alcohol-Related Disorders
Altimmune has secured a $100 million credit facility from Hercules Capital, with $15 million funded immediately and additional tranches available upon meeting clinical and financial milestones.
Boehringer Ingelheim and Tessellate Bio Form €500M Partnership to Target ALT-Positive Cancers
Boehringer Ingelheim has secured global commercialization rights for treatments co-developed with Tessellate Bio targeting tumors dependent on alternative lengthening of telomeres (ALT), present in 10-15% of all cancers.
Altimmune Expands Pemvidutide Testing to Alcohol Use Disorder and Liver Disease
Altimmune announced plans to initiate Phase II trials of its GLP-1/glucagon agonist pemvidutide for alcohol use disorder in Q2 2025 and alcohol-related liver disease in Q3, expanding beyond obesity treatment.
Altimmune Halts Nasal COVID-19 Vaccine Development After Poor Phase 1 Results
Altimmune's intranasal COVID-19 vaccine AdCOVID showed insufficient immune response in Phase 1 trials, leading to the termination of the development program.
Emerging Biotechs Vie for Position in Lucrative GLP-1RA Market Dominated by Novo Nordisk and Eli Lilly
Altimmune's pemvidutide, currently in Phase II trials for obesity and metabolic dysfunction-associated steatohepatitis, is projected to reach $1.21 billion in sales by 2030.
Altimmune and MindMed Join Nasdaq Biotechnology Index, Anticipate Key Clinical Data in 2025
Altimmune and MindMed were added to the Nasdaq Biotechnology Index (NBI) on December 23, 2024, signaling recognition of their progress and potential.
Omaveloxolone Shows Positive Long-Term Safety Profile in Friedreich Ataxia
Long-term analysis of omaveloxolone demonstrates a favorable safety profile for treating Friedreich ataxia, with most adverse events being manageable.
Semaglutide 2.4 mg Shows Promise in MASH Treatment: Phase 3 ESSENCE Trial Results
Semaglutide 2.4 mg demonstrated statistically significant improvements in liver fibrosis and resolution of steatohepatitis in MASH patients compared to placebo.
Altimmune's Pemvidutide Shows Promise in Obesity Treatment with Strategic Phase III Development
Altimmune's pemvidutide advances to Phase III obesity program following successful FDA meeting, incorporating an innovative design targeting diverse patient subpopulations.
Altimmune's Pemvidutide Obesity Program Gains FDA Agreement on Phase 3 Design
Altimmune has reached an agreement with the FDA on the design of its Phase 3 program for pemvidutide in treating obesity, marking a significant regulatory milestone.